While loss of STK11 and PTEN significantly reduced overall survival (32.71 or 46.72 vs. 58.45 months, respectively), mutations in any of the four tumor suppressors negatively affected disease-free and progression-free survival (Figure 4C and Supplementary Figures 4B,C). Here, PTEN is linked to neoplasm.